TECHNICAL AND SCIENTIFIC GUIDE

CBL-514: Pharmacology, Clinical Evidence and Therapeutic Outlook

Updated 29 July 2026

Intended audience: researchers, graduate students, and clinicians in aesthetic medicine, endocrinology and pharmacology

1. Preliminary note on terminology: CBL-514 is not a peptide

This is the first point that needs correcting across virtually all grey literature and in the marketing material of “research use only” suppliers:

• CBL-514 is a synthetic small molecule — not a peptide, not a recombinant protein, and not a hormone analogue.
• It is regulated as a new drug under the 505(b)(1) pathway with the FDA — the same route as any new chemical entity, and not the biologics or generics pathway.
• Developer: Caliway Biopharmaceuticals (Taiwan, TWSE: 6919), founded in 2012.
• The exact chemical structure remains under patent protection and has not been publicly disclosed in peer-reviewed publications — only the molecular target and the biomarkers of effect.

Practical implication: material sold as “CBL-514 peptide” through research supply channels does not correspond to the entity described in the clinical trials, since the clinical molecule cannot be sequenced as a peptide and is not available outside sponsored protocols. Any identity analysis (HPLC/MS) of such products should be treated as unverifiable against a public reference standard.

2. Mechanism of action

2.1 Molecular target

The mechanism described in the clinical protocols and in the published literature is inhibition of DYRK1B (dual-specificity tyrosine-phosphorylation-regulated kinase 1B, also known as Mirk).

Relevant biological context for DYRK1B:

• A dual-specificity kinase, highly expressed in adipose tissue, skeletal muscle and liver.
• Involved in the differentiation of preadipocytes into mature adipocytes and in maintaining cells in quiescence (G0), acting as a survival factor under nutrient stress.
• Suppresses SHH and WNT1 signalling, thereby promoting adipogenesis.
• Mutations in DYRK1B have been associated with metabolic syndrome phenotypes in humans, which strengthens the plausibility of the target.

2.2 Effector cascade

Inhibition of DYRK1B in the mature adipocyte triggers apoptosis through the intrinsic (mitochondrial) pathway, documented by:

• Increased expression of cleaved caspase-3
• Increased Bax/Bcl-2 ratio
• Absence of a necrosis signature in preclinical models and clinical assessments

2.3 The key differentiator: apoptosis ≠ necrosis ≠ classical lipolysis

Approach	Mechanism	Tissue consequence
Deoxycholic acid (Kybella / Belkyra)	Detergent — membrane lysis	Adipocyte necrosis, intense inflammation, risk of damage to adjacent structures; limited to small areas (submentum)
Cryolipolysis	Cold-induced apoptosis	Area restricted to the applicator, variable response
GLP-1 / GIP receptor agonists	Reduced intake → reduced adipocyte volume	Adipocyte number preserved; re-expansion after discontinuation
CBL-514	DYRK1B inhibition → selective apoptosis	Reduction in the absolute number of adipocytes at the injection site; physiological clearance of apoptotic bodies

This is the central argument of the programme: incretin-based drugs shrink the adipocyte; CBL-514 eliminates the adipocyte. That changes the nature of the response in terms of durability and body composition.

3. Pharmacological and safety profile

• Route of administration: multi-point subcutaneous injection into the adipose layer (protocols with up to 60 injection points per session), with unit dose expressed in mg/cm² of treated area.
• Typical dose in the pivotal studies: 2.0 mg/cm², capped at ≤600 mg per session; 3- to 4-week intervals, up to 4 sessions.
• Predominant adverse events: injection site reactions (ISRs) — swelling, erythema, pain, bruising — mild to moderate and transient.
• No drug-related serious adverse events reported in completed studies; no systemic signals affecting the central nervous, cardiovascular or respiratory systems.
• Local versus systemic metabolic safety: a critical theoretical question is whether large-scale adipocyte apoptosis would release enough lipid to alter the systemic lipid profile. In the Phase 2b CBL-0204 analysis, mean changes in total cholesterol and triglycerides were minimal and comparable to placebo at 4- and 8-week follow-up — suggesting no clinically meaningful short-term lipid repercussion.

4. Consolidated clinical evidence

As of July 2026: 10 completed clinical studies with finalised statistical reports, more than 544 participants exposed, with all primary and key secondary endpoints met.

4.1 Localised subcutaneous fat reduction

Phase 2a (CBL-16001) — published in 2022

• Randomised design, doses of 1.2 / 1.6 / 2.0 mg/cm², up to 4 treatments.
• Abdominal fat volume reduction of 24.96% at the highest dose (ultrasound assessment).
• Established the dose-response relationship and the 2.0 mg/cm² dose used in subsequent studies.

Phase 2b (CBL-0204, NCT05736107) — published in the Aesthetic Surgery Journal, May 2026

• 108 adults with moderate (Grade 3) to severe (Grade 4) abdominal fat accumulation, randomised 1:1, placebo-controlled, single-blind.
• Primary endpoint: ≥1-grade improvement on the CR-AFRS (clinician-reported scale) at 12 weeks — 76.7% (23/30) vs. 18.9% (7/37) with placebo (p<0.0001).
• PR-AFRS (patient-reported): 76.7% vs. 19.4% (p<0.0001) — notable agreement between clinician assessment and patient perception.
• MRI: least-squares mean reduction of −152.9 mL ± 17.75, corresponding to −20.3% of baseline volume (p<0.0001 vs. placebo).
• Most responders achieved ≥1-grade improvement after just 1 to 2 sessions.

Phase 2b (CBL-0205)

• 173 participants — the largest study in the programme at the time; multicentre, double-masked (participant and outcomes assessor), approved by the FDA and Health Canada.
• Primary endpoint met; safety profile consistent, with no drug-related SAEs.
• In a programme sub-analysis, roughly 70% of participants reduced ≥150 mL and more than 60% reduced ≥200 mL in the treated area.

4.2 Cellulite (edematous fibrosclerotic panniculopathy — EFP)

CBL-0201EFP (Phase 2, stages 1 and 2)

• Assessed with the modified Hexsel Cellulite Severity Scale (mHCSS), 0–9 points.
• All primary and secondary endpoints met in the ITT and PP populations.
• Stage 2: 23 participants, up to 2 treatments on the thighs, maximum single dose of 320 mg, 4-week intervals; mean baseline score 6.5 ± 1.0. More than 50% of participants improved by at least one severity level.
• Stated differentiator: it is the only candidate acting on the raised area (the protruding adipose component) of cellulite, rather than only on the fibrous septal bands — the target of clostridial collagenase (Qwo).

4.3 Dercum’s disease (adiposis dolorosa) — CBL-514D formulation

A rare disease characterised by painful lipomas on the trunk and proximal limbs, with chronic (>3 months), symmetrical pain that is frequently disabling and resistant to conventional analgesics. No approved treatment exists.

CBL-0201DD (Phase 2, NCT05387733)

• 64.5% of painful lipomas showed >50% dimensional reduction or complete clearance (per-protocol population).
• 38.7% of lipomas achieved complete clearance.
• 54.8% met the endpoint after a single treatment.
• Mean reduction of 4.7 points on the comparative pain scale (0–10), p<0.0001 — a clinically very meaningful magnitude.

Exceptional regulatory status:

• Orphan Drug Designation (FDA, March 2024) and Fast Track Designation (FDA, February 2024) — the first and only drug to hold both designations for Dercum’s disease.
• EMA Orphan Drug Designation (November 2024), carrying 10 years of EU market exclusivity upon approval.
• CBL-0202DD (Phase 2b, NCT06303570), placebo-controlled, ongoing in the United States — topline results expected in Q3 2026.

5. Ongoing Phase 3 programme

Study	Scope	Status (Jul 2026)
SUPREME-01 (CBL-0301)	Global pivotal, ~300 subjects, 29 sites across the US and Canada, randomised 1:1	IND cleared by the FDA in Jul 2025; recruitment underway
SUPREME-02 (CBL-0302)	Global pivotal, ~320 subjects, US / Canada / Australia, double-blind	IND cleared (30-day review completed May 2026); CTA approved by Health Canada
CBL-0303	Phase 3b long-term follow-up — 12-month safety after discontinuation (NDA requirement)	IND cleared by the FDA in Jul 2026
CBL-0206	Asia-Pacific Phase 2 — data in an Asian population	Approved by HREC (Australia) and TFDA (Taiwan); enrolment initiated in Australia
CBL-0304	Phase 3 in China	Submission planned for H2 2026

Primary endpoint design (methodologically relevant): a multicomponent responder endpoint combining (1) change in abdominal subcutaneous fat volume measured by MRI — an objective, quantifiable measure — and (2) PR-AFRS, a patient-reported scale. This is a deliberate departure from the historical aesthetic-medicine standard of subjective visual assessment, and it underpins the claim to a medical indication (“reduction of abdominal subcutaneous fat”) rather than the classical cosmetic indication (“improvement in appearance”).

SUPREME-01 topline results are expected between Q4 2026 and Q1 2027; the full pivotal dataset in 2027.

6. The most consequential frontier: combination with GLP-1/GIP agonists

Scientifically, this is the most interesting line of the programme and the one that extends CBL-514 from aesthetics into metabolic medicine.

6.1 Pathophysiological rationale

• GLP-1R agonists and dual GIP/GLP-1R agonists drive weight loss primarily through appetite suppression, reducing adipocyte size, not number.
• Visceral fat responds faster than subcutaneous fat, producing uneven reduction and leaving resistant subcutaneous depots (abdomen, flanks).
• Subcutaneous adipose tissue in these regions possesses biological mechanisms that resist lipolytic signalling, contributing to the weight-loss plateau.
• Because adipocytes remain present and merely contracted, the return of normal appetite after discontinuation drives rapid re-expansion — weight regain with worsened body composition.

6.2 Preclinical data (OI25 study — ADA 2026 and ECO 2026)

CBL-514 combined separately with semaglutide and tirzepatide in an animal model:

• Weight regain after discontinuation: 46.1% in the tirzepatide monotherapy group vs. 17.1% in the combination group — a rebound effect 2.7 times greater without CBL-514.
• An additional 106.7% reduction in liver fat in the combination group.
• Significant improvement in insulin resistance (HOMA-IR).
• Greater reductions in both subcutaneous and visceral fat.

Important methodological caveat: these percentages are expressed as relative differences between groups (e.g. “an additional 106.7% reduction”), a corporate communication convention that can inflate the perceived magnitude. These are animal data, not clinical data, and have not yet been published in a peer-reviewed journal.

6.3 Clinical translation: CBL-0201WR

• IND submitted to the FDA on 27 July 2026.
• Randomised, placebo-controlled, multicentre Phase 2 study, 120 subjects in the United States.
• Proposed indication: reduction of abdominal subcutaneous fat in adults with overweight or obesity, in combination with Zepbound® (tirzepatide, Eli Lilly).
• Primary endpoint: change in abdominal subcutaneous fat volume measured by MRI.
• Key secondary endpoints: total body weight, visceral adipose tissue and lean body mass.
• Clinical data on visceral fat reduction has been selected for an oral presentation at EASD 2026 (September), delivered by Dr W. Timothy Garvey.

7. Plausible human therapeutic indications (2027–2032 horizon)

High probability (contingent only on the pivotal readouts):

• Non-surgical reduction of abdominal subcutaneous fat over large areas.
• Moderate-to-severe cellulite (EFP) — the first agent to act on the raised adipose component.

Moderate-to-high probability (orphan pathway, robust Phase 2 evidence):

• Dercum’s disease — potential first-in-class, with dual FDA and EMA designation; contingent on CBL-0202DD.
• Isolated painful lipomas and, by conceptual extension, other painful lipomatoses.

Exploratory / declared in the pipeline:

• Weight-loss maintenance and mitigation of post-GLP-1 regain — the indication with the greatest clinical and commercial potential.
• Obstructive sleep apnoea (OSA) — via reduction of peripharyngeal/cervical adipose depots, a declared indication for the CBL-514D formulation.
• Adjacent metabolic health: hepatic steatosis and insulin resistance, suggested by the OI25 data, with no dedicated clinical programme as yet.

Reasonable hypotheses with no announced programme: lipoedema, antiretroviral-associated lipodystrophy, multiple symmetric lipomatosis (Madelung disease).

8. Critical limitations and evidence gaps

A scientific reader should weigh the following:

1. Provenance of the data. Nearly all the evidence is generated and communicated by the sponsor. Only three studies have undergone peer review, all in the same journal (Aesthetic Surgery Journal) and with Caliway co-authorship.
2. Imperfect masking. CBL-0204 is single-blind; pronounced injection site reactions make participant masking intrinsically fragile in any design — which bears on patient-reported outcomes (PR-AFRS).
3. Small and asymmetric samples. Analysis populations of around 30 per arm for the Phase 2b primary endpoints; several cellulite and Dercum studies are open-label and single-arm.
4. Absence of long-term durability data. This is precisely why CBL-0303 (12 months post-discontinuation) exists. Without it, the central question remains unanswered: is the reduction in adipocyte number permanent, or is there compensatory hyperplasia from resident preadipocytes?
5. Metabolic fate of released lipids. Short-term data are reassuring, but there is no characterisation of apoptotic body clearance, of the response of adipose tissue resident macrophages, or of hepatic lipid flux in humans.
6. Undisclosed chemical structure. This prevents independent characterisation, third-party structure-activity studies, and verification of DYRK1B inhibition selectivity against other kinases of the DYRK/CLK family.
7. Population homogeneity. Most data come from Western populations; hence CBL-0206 in Asia-Pacific.
8. Human pharmacokinetics are sparsely described in the public literature (systemic exposure, half-life, metabolism).

9. Regulatory status and safety note

• CBL-514 is not approved by any regulatory agency anywhere in the world — not the FDA, EMA, ANVISA or TFDA. It is an investigational drug.
• Outside an authorised clinical protocol, no legitimate source of the molecule exists for human use.
• Material sold as “CBL-514” through research supply channels lacks a public reference standard for identity verification, and any human use is unauthorised and unsupported by safety data.
• In June 2026, Caliway itself issued a public statement denying claims of a commercial partnership circulated by a third party — a sign that market interest has already produced misappropriation of the asset name.

10. Key references

• Lorenc ZP, Gold M, Schlessinger J, et al. Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment. Aesthetic Surgery Journal, 2026; sjag092. DOI: 10.1093/asj/sjag092
• Goodman GJ, Ho WWS, Chang KJ, et al. Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction. Aesthetic Surgery Journal, 2022.
• ClinicalTrials.gov: NCT05736107 (CBL-0204), NCT05387733 (CBL-0201DD), NCT06303570 (CBL-0202DD), NCT05836779 (CBL-0201EFP), NCT04575467 (protocol containing the mechanism description).
• Caliway Biopharmaceuticals — corporate releases and R&D page: https://www.caliwaybiopharma.com/en/research/15/
• Kokkorakis N, Gaitanou M. DYRK1B in adipogenesis and glucose homeostasis — reference review on the molecular target.
• OI25 preclinical data, presented at ADA 2026 (Scientific Sessions) and ECO 2026; clinical visceral fat data selected for oral presentation at EASD 2026.

Prepared from publicly available information as of 29 July 2026. This document is technical and informational in nature; it does not constitute clinical advice nor an endorsement of the use of an investigational substance.